A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
Public ClinicalTrials.gov record NCT01054443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Study identification
- NCT ID
- NCT01054443
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Shionogi
- Industry
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- Lusutrombopag Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2010
- Primary completion
- Nov 23, 2010
- Completion
- Nov 23, 2010
- Last update posted
- Mar 17, 2021
2010
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator | Anaheim | California | 92801 | — |
| Investigator | Los Angeles | California | 90272 | — |
| Investigator | Washington D.C. | District of Columbia | 20007 | — |
| Investigator | Boynton Beach | Florida | 33426 | — |
| Investigator | Jacksonville | Florida | 32207 | — |
| Investigator | Atlanta | Georgia | 30341 | — |
| Investigator | Riverdale | Georgia | 30274 | — |
| Investigator | Metairie | Louisiana | 70006 | — |
| Investigator | Bethesda | Maryland | 20817 | — |
| Investigator | Boston | Massachusetts | 02114 | — |
| Investigator | Jefferson City | Missouri | 65109 | — |
| Investigator | Kansas City | Missouri | 64131 | — |
| Investigator | New Brunswick | New Jersey | 08903 | — |
| Investigator | New York | New York | 10021 | — |
| Investigator | New York | New York | 10029 | — |
| Investigator | Cleveland | Ohio | 44106 | — |
| Investigator | San Antonio | Texas | 78229 | — |
| Investigator | Salt Lake City | Utah | 84132 | — |
| Investigator | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01054443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2021 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01054443 live on ClinicalTrials.gov.